Such technologies are widely used in biological
research and in medicine, such as toward prognosis and therapy response prediction in cancer patients. More recently, systems biology is being applied to vaccinology, with the goal of: (1) understanding the mechanisms by which vaccines stimulate protective immunity, and (2) predicting the immunogenicity or efficacy of vaccines. Here, we review the recent advances in this area, and highlight the biological and computational challenges posed. WIREs Syst Biol Med 2012, 4:193205. doi: 10.1002/wsbm.163″
“Objective: To review federal, state, and local antiobesity policies and to assess their relationships with obesity selleck screening library growth rates.
Methods: We performed a literature review, acquired data from governmental Internet sources, and assessed the statistical correlation between state antiobesity policies and the concavity in obesity growth. rates.
Results: State-by-state antiobesity policies in 3 categories taxation of sugared beverages and snacks, physical education
and physical activity in schools, and funding for bicycle trails were found to have no significant immediate correlation with the change in obesity growth rates.
Conclusions: Ineffective antiobesity legislation may be attributable to shortcomings in policy implementation. Behavioral economics and addressing large-scale cultural issues may have critical roles in promoting more healthful lifestyles. We propose that a systems-based paradigm evaluating complex interactions among pathophysiological,
IWP-2 cost cultural, political, economic, and behavioral components can improve antiobesity policy implementation and should therefore be a research focus. (Endocr Pract. 2012;18:737-744)”
“BackgroundRecently, we showed that combination of omalizumab with specific immunotherapy (SIT) for treatment of patients with seasonal allergic rhinitis (SAR) and comorbid seasonal allergic asthma (SAA) is safe and reduced the symptom load in a statistically significant and clinically meaningful manner during the first pollen season.
ObjectiveThe aim of this study was to investigate long-lasting effects of an initial combination treatment with SIT+omalizumab, a monoclonal Selleckchem Eltanexor anti-IgE antibody, in a follow-up period with SIT treatment only in patients with SAR and comorbid SAA incompletely controlled by conventional pharmacotherapy.
MethodsA randomized, double-blind, placebo-controlled, multicenter trial was performed to assess the efficacy and safety of omalizumab (Xolair((R))) vs. placebo in combination with SIT (depigmented allergoid vaccine, Depigoid((R))) during the first grass pollen season. Omalizumab or placebo therapy was started 2wk before SIT; the whole treatment lasted 18wk. After the first pollen season, SIT was given for two subsequent years without omalizumab.